

**Preview | Oral Presentation at ESMO Asia 2025: First-in-Human Results
of ES014, the World's First CD39/TGF- β Bispecific Antibody, as
Monotherapy in Advanced Solid Tumors to Be Unveiled**

Elpiscience announced that the first-in-human Phase I clinical results of ES014, the world's first-in-class CD39/TGF- β bispecific antibody developed in-house, will be presented as an oral presentation at the Proffered Paper Session during ESMO Asia 2025, scheduled to take place on December 5, 2025, in Singapore.

ES014 is the first-in-class and first clinical-stage CD39/TGF- β bsAb worldwide independently developed by Elpiscience, which targets two different immunosuppressive pathways in the tumor microenvironment (TME) : the CD39 – adenosine pathway and the TGF- β pathway. ES014 has demonstrated favorable safety and antitumor activity in preclinical studies, supporting its potential to treat a wide range of solid tumors. In December 2022, the company received IND approval from China's National Medical Products Administration (NMPA) to initiate the Phase I clinical trial. The ongoing study evaluates ES014 as monotherapy in patients with advanced solid tumors and has completed patient enrollment, including dose escalation and expansion cohorts.

Data from the Phase I study, to be presented in the oral presentation at ESMO Asia 2025, shows that ES014 has exhibited a favorable safety profile and encouraging antitumor activity across multiple tumor types, including non-small cell lung cancer (NSCLC), Desmoid Tumors(DT), and gastrointestinal stromal tumors (GIST).

The selection of ES014 for an oral presentation in the Proffered Paper Session highlights its strong potential in addressing CD39-high solid tumors and provides important clinical evidence to support further development of ES014.

Presentation Details:

- Presentation Title: First-in-human study of ES014, a bispecific antibody targeting CD39 and TGF- β as monotherapy in patients with advanced solid tumors
- Presentation Number: 1590
- Speaker: Zhen Zhou, M.D., Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University, School of Medicine
- Session: Proffered Paper Session: Developmental therapeutics and precision medicine
- Date: December 5, 2025, 11:25 – 11:35
- Location: Hall 401, Suntec Singapore, Singapore

About ESMO Asia

The ESMO Asia Congress, organized by the European Society for Medical Oncology (ESMO), is one of the most influential oncology events in the Asia-Pacific region, dedicated to advancing cancer research and clinical practice across Asia.

The ESMO Asia Congress 2025 will take place from December 5 to 7 in Singapore. The meeting will bring together leading experts to discuss cutting-edge topics including precision medicine, biomarkers, innovative cancer therapies, and cancers with high prevalence in the Asia-Pacific region, with in-depth presentations of the year's most significant research breakthroughs.

About Elpiscience

Elpiscience is a clinical-stage biopharmaceutical company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. By advancing breakthrough biologics and leveraging global strategic partnerships, Elpiscience has built a differentiated pipeline to deliver transformative treatment solutions for patients worldwide.

BD inquiries:

BD@elpiscience.com

Media inquiries:

PR@elpiscience.com